[Antifibrotic therapy in other fibrotic interstitial lung diseases than idiopathic pulmonary fibrosis]

Ugeskr Laeger. 2021 Dec 6;183(49):V04210348.
[Article in Danish]

Abstract

Numerous studies have shown that perioperative heparin bridging in patients treated with a vitamin K antagonist leads to an increased incidence of bleeding and so far, there is no evidence that it leads to a significant reduction in postoperative thromboembolism as summarised in this review. Prophylactic dosage of heparin is recommended after major surgery. Heparin bridging is not relevant in patients receiving a direct oral anticoagulant due to the rapid onset and offset of action of DOACs.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Heparin
  • Humans
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • Lung Diseases, Interstitial* / drug therapy
  • Vitamin K

Substances

  • Anticoagulants
  • Vitamin K
  • Heparin